AMRX (Amneal Pharmaceuticals, Inc.) Net Profit

Corporate emblem and logo of amneal.com (AMRX)

Amneal Pharmaceuticals (AMRX) faces pricing pressure on generics and patent risks. The company's aggregate profit on this chart demonstrates resilient financial returns, where 0.16 reflects the latest metric value. Growth is driven by the implementation of complex injectables and biosimilars, while a stable cash flow is maintained through a broad spectrum of affordable medicines.

AMRX (Amneal) Company Net Income history from 07/04/2022 to 11/01/2026

Financial and market metric breakdowns for Amneal (AMRX)

- price and consensus price forecast:
Stock Quotes Amneal Corp|AMRX - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Amneal Corp|AMRX - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Amneal Pharmaceuticals|AMRX - Company Book Value|Market-to-Book Ratio amneal.com|AMRX - Cumulative Company Assets
- debt and solvency information:
Aggregate Debt to Capital Amneal Pharmaceuticals|AMRX - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Amneal Pharmaceuticals, Inc.|AMRX - Company Aggregate Debts|Debts to Book Value Amneal Corp|AMRX - Company Long-Term Debt|Company Short-Term Loans and Borrowings Amneal Pharmaceuticals|Quick Ratio amneal.com
- net income and valuation multiples indicators:
AMRX - Company Net Income
Fundamental valuation:AMRX Amneal Corp
Flagship merchandise of Amneal Pharmaceuticals, Inc.

To filter for high-quality assets, investors must distinguish market noise from actual operational efficiency in capital management. This indicator measures daily profit, reflecting the ability of Amneal Pharmaceuticals (AMRX) to generate a stable cash flow regardless of macroeconomic shocks, which confirms the resilience of non-cyclical generic production through an analysis of the company's aggregate net income.

Main competitors

Net Income Haleon Corp|KVUE (Kenvue Inc.) - Net Profit|Net Profit veronapharma.com|Net Income MENS (Jyong Biotech)|LGND (Ligand Pharmaceuticals Incorporated) - Final Profit|Company Net Income Perrigo Company PRGO|Alvotech Biopharmaceuticals (ALVO) - Company Net Income|LQDA: Net Income|glpg.com - Profit After Payment of Taxes|ANIP: Net Profit|MannKind Corp - Final Profit|AMPH (Amphastar) - Net Profit|Company Net Income Pacira Corp PCRX|Company Net Income ARS Pharmaceuticals (SPRY)|TBPH (theravance.com) - Final Profit|Net Profit AQST (Aquestive Therapeutics, Inc.)|Net Profit scPharmaceuticals, Inc. SCPH|TECX - Company Net Income|Tonix Pharmaceuticals Holding (TNXP) - Net Income|sxtchina.com (SXTC) - Company Net Income|Company Profit EPRX|BHST (BioHarvest Sciences Inc.) - Net Profit|Company Net Income Invizyne Technologies EXOZ|Net Profit ORMP|Net Profit enterabio.com (ENTX)|Company Net Income MindWalk Holdings HYFT|abvcpharma.com - Company Net Income|CPIX: Net Income|Final Profit QNTM (Quantum BioPharma Ltd.)|FibroGen Corp (FGEN) - Company Net Income|Profit After Tax TELO (Telomir Pharmaceuticals Corp)|RANI (Rani Therapeutics Holdings) - Net Profit|SNYR: Final Profit|Net Profit RLYB|Net Profit lexariabioscience.com (LEXX)|Company Net Income Pulmatrix Corp PULM|Final Profit PTHL|APM - Company Net Income|lyratherapeutics.com (LYRA) - Net Income|IBO: Net Profit|TNF Pharmaceuticals, Inc. (TNFA) - Net Profit|YCBD (cbdMD Inc.) - Net Profit|Net Income PainReform Corp (PRFX)|Net Profit CYTO|LIPO - Company Net Income|OptiNose - Net Income|Net Profit Pieris Pharmaceuticals Inc PIRS|PROC: Net Income|Petros Pharma - Profit After Payment of Taxes|QLI: Net Profit|SLRN - Net Financial Result|TFFP (TFF Pharmaceuticals, Inc.) - Net Profit